The Centers for Medicare & Medicaid Services issued a proposed rule that, if finalized, would modify significantly the current Medicaid Drug Rebate Program regulations. The proposed rule puts forth new regulatory policies, as well as provides clarification with regard to already established policies, intended to encourage drug manufacturers and states to participate in value-based purchasing arrangements.
In a Law360 article, health care partner Tom Bulleit summarizes key elements of the proposed rule and its implications.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.